BridgeMD
New treatment option for Neoplasm Malignant
Official title A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
ClinicalTrials.gov ID: NCT07209111
What this study is testing
What is Calderasib?
Calderasib is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for neoplasm malignant.
Also referred to as MK-1084.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- The main include but are not limited to the following:
- Has locally advanced unresectable or metastatic solid tumor malignancy other than colorectal cancer and has progressed on, or following, standard of...
- Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation
You likely can't join if
- The main exclusion criteria include but are not limited to the following:
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system metastases and/or carcinomatous meningitis and/or primary brain tumors
- Has active infection, other than those permitted per protocol, requiring systemic therapy
- Has not adequately recovered from major surgery or has ongoing surgical complications
The study team makes the final eligibility decision.
Where it's taking place
- Baltimore, Maryland, United States
- Grand Rapids, Michigan, United States
- Las Vegas, Nevada, United States
- New Brunswick, New Jersey, United States
- West Valley City, Utah, United States
- Fairfax, Virginia, United States
- Randwick, New South Wales, Australia
- Westmead, New South Wales, Australia
- Melbourne, Victoria, Australia
- Montreal, Quebec, Canada
- Santiago, Region M. de Santiago, Chile
- Beijing, Beijing Municipality, China
- Xiamen, Fujian, China
- Guangzhou, Guangdong, China
- Harbin, Heilongjiang, China
- Wuhan, Hubei, China
- Nanjing, Jiangsu, China
- Nanchang, Jiangxi, China
- Jinan, Shandong, China
- Shanghai, Shanghai Municipality, China
+ 31 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Baltimore, Maryland, United States; Grand Rapids, Michigan, United States; Las Vegas, Nevada, United States; New Brunswick, New Jersey, United States; West Valley City, Utah, United States; Fairfax, Virginia, United States and 45 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.